Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 19.6, while the current price is HKD 16.22 [6]. Core Insights - The company achieved a revenue of RMB 1.14 billion and a net profit attributable to shareholders of RMB 120 million in the first half of 2024, with significant growth in the women's care center business [1][2]. - Revenue growth was driven by franchise stores and sub-health services, with women's care center revenue increasing over 200% year-on-year [2]. - The acquisition of 150 stores from Nairu, covering the Greater Bay Area, further expands the company's business footprint and complements its existing services [4]. Financial Performance - For the first half of 2024, the company reported a revenue increase of 9.7% year-on-year, while net profit grew by 3.2% [2]. - The gross margin slightly increased by 0.9 percentage points to 47.0%, attributed to increased customer traffic and economies of scale [2]. - The company forecasts net profits for 2024-2026 to be RMB 250 million, RMB 320 million, and RMB 370 million, respectively, with corresponding P/E ratios of 14.1x, 10.9x, and 9.5x [4]. Store Expansion and Customer Engagement - The company has expanded its store count to over 559, including 150 Nairu stores, with a significant increase in customer traffic and active membership [3]. - Direct store traffic reached 680,000 visits, a 12% increase year-on-year, while active members grew by 10% to 82,000, maintaining a high retention rate of 79% [3].
美丽田园医疗健康：收购奈瑞儿辐射大湾区，女性特护中心同比增长超200%